Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Dow
Mallinckrodt
Harvard Business School
Moodys

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR RUBRACA


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Rubraca

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02740712 ↗ Pharmacokinetic Drug-Drug Interaction Study of Rucaparib Completed Clovis Oncology, Inc. Phase 1 2016-04-01 The purpose of this study is to assess pharmacokinetic concentrations of multiple probes alone followed by assessment of the same drug pharmacokinetic concentrations when the patient has steady-state exposure to rucaparib followed by cycle-by-cycle treatment with rucaparib continuing until disease progression or other reason for discontinuation.
NCT02855944 ↗ ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Active, not recruiting Foundation Medicine Phase 3 2017-03-01 The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
NCT02855944 ↗ ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Active, not recruiting Clovis Oncology, Inc. Phase 3 2017-03-01 The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
NCT02873962 ↗ A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib Recruiting Bristol-Myers Squibb Phase 2 2016-11-10 This research study is evaluating three drugs called Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed Relapsed Ovarian, Fallopian Tube Or Peritoneal Cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Rubraca

Condition Name

Condition Name for Rubraca
Intervention Trials
Fallopian Tube Cancer 5
Epithelial Ovarian Cancer 4
Ovarian Cancer 4
Solid Tumor 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Rubraca
Intervention Trials
Fallopian Tube Neoplasms 6
Ovarian Neoplasms 6
Carcinoma, Ovarian Epithelial 4
Prostatic Neoplasms 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Rubraca

Trials by Country

Trials by Country for Rubraca
Location Trials
United States 93
Canada 16
Japan 15
Brazil 12
United Kingdom 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Rubraca
Location Trials
California 6
Georgia 5
New York 5
Massachusetts 4
Washington 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Rubraca

Clinical Trial Phase

Clinical Trial Phase for Rubraca
Clinical Trial Phase Trials
Phase 3 3
Phase 2 8
Phase 1/Phase 2 3
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Rubraca
Clinical Trial Phase Trials
Recruiting 7
Active, not recruiting 7
Completed 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Rubraca

Sponsor Name

Sponsor Name for Rubraca
Sponsor Trials
Clovis Oncology, Inc. 19
Bristol-Myers Squibb 6
Foundation Medicine 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Rubraca
Sponsor Trials
Industry 45
Other 13
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Johnson and Johnson
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.